Athersys, Inc. (NASDAQ:ATHX) – Equities research analysts at William Blair issued their Q1 2018 EPS estimates for Athersys in a report released on Thursday. William Blair analyst Y. Xu anticipates that the biopharmaceutical company will earn ($0.09) per share for the quarter. William Blair also issued estimates for Athersys’ Q2 2018 earnings at ($0.10) EPS, Q3 2018 earnings at ($0.11) EPS and Q4 2018 earnings at ($0.12) EPS.

A number of other analysts have also commented on ATHX. Maxim Group set a $12.00 price target on Athersys and gave the company a “buy” rating in a report on Monday, August 7th. Zacks Investment Research upgraded Athersys from a “hold” rating to a “buy” rating and set a $1.75 price target on the stock in a report on Monday, August 14th. Finally, ValuEngine upgraded Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th. One research analyst has rated the stock with a sell rating and four have given a buy rating to the company’s stock. Athersys presently has an average rating of “Buy” and a consensus target price of $7.17.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/10/06/william-blair-weighs-in-on-athersys-inc-s-q1-2018-earnings-athx.html.

Shares of Athersys (NASDAQ:ATHX) traded down 1.6612% during mid-day trading on Friday, hitting $2.4093. The stock had a trading volume of 444,313 shares. The firm’s 50-day moving average price is $2.04 and its 200 day moving average price is $1.64. Athersys has a 12-month low of $1.02 and a 12-month high of $2.63. The stock’s market cap is $274.45 million.

Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.06). The business had revenue of $0.67 million during the quarter, compared to analyst estimates of $0.96 million. Athersys had a negative return on equity of 121.47% and a negative net margin of 729.07%. The company’s revenue was up 12.4% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.08) earnings per share.

Several institutional investors have recently modified their holdings of the company. The Manufacturers Life Insurance Company lifted its holdings in shares of Athersys by 345.5% in the second quarter. The Manufacturers Life Insurance Company now owns 88,561 shares of the biopharmaceutical company’s stock valued at $134,000 after purchasing an additional 68,680 shares in the last quarter. State Street Corp lifted its holdings in shares of Athersys by 27.2% in the second quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock valued at $2,161,000 after purchasing an additional 305,944 shares in the last quarter. Royal Bank of Canada lifted its holdings in shares of Athersys by 7,334.0% in the second quarter. Royal Bank of Canada now owns 380,846 shares of the biopharmaceutical company’s stock valued at $576,000 after purchasing an additional 375,723 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Athersys by 9.4% in the second quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock valued at $6,441,000 after purchasing an additional 366,572 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Athersys by 30.8% in the second quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock valued at $1,697,000 after purchasing an additional 264,549 shares in the last quarter. Institutional investors own 19.08% of the company’s stock.

In other news, EVP John J. Harrington sold 15,000 shares of the business’s stock in a transaction dated Monday, September 18th. The stock was sold at an average price of $2.17, for a total value of $32,550.00. Following the sale, the executive vice president now directly owns 679,416 shares in the company, valued at $1,474,332.72. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 9.40% of the company’s stock.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Earnings History and Estimates for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys Inc. and related companies with MarketBeat.com's FREE daily email newsletter.